Investor Presentation Full Year 2021
13
Investor presentation
Full year 2021
Novo NordiskⓇ
Continued progress of the pipeline with trial read outs and phase
3 starts during fourth quarter of 2021
SogroyaⓇ | Phase 3 trial completion
Phase 3 programme in 200 children
with GHD successfully completed
• REAL 4 compared efficacy and safety of
once-weekly SogroyaⓇ vs daily
NorditropinⓇ
The trial met the primary end-point of
non-inferiority in height velocity vs
Norditropin®
Biopharm
•
Mim8| Phase 1/2 trial interim results
Successfully completed first cohorts of
on-going phase 1/2 clinical proof of
concept trial with Mim8
Appeared to have a safe and well-
tolerated profile, with PK/PD properties
supporting once-weekly as well as
once-monthly dosing
Remaining two cohorts expected to
read out in Q1 2022
Diabetes care
Icosema | Phase 3 programme initiation
•
•
Icosema is a fixed dose combination of
insulin icodec and semaglutide in a
once weekly injection
The first of three trials in the COMBINE
progamme has been initiated in Q4
2021
• The objectives are to confirm efficacy
and safety of icosema
Expect to submit Sogroya® for
regulatory approval during H1 2022
Expect to initiate Mim8 treatment
during H2 2022 in on-going phase 3 trial
Expect to complete phase 3a
programme during 2024
GHD: Growth hormone deficiency; PK: Pharmacokinetics; PD: PharmacodynamicsView entire presentation